| COVID-19 |
1 |
1 |
| Biologic Therapy |
0 |
0.99 |
| Acute Leukemia |
0 |
0.87 |
| Acute Myeloblastic Leukemia |
0 |
0.63 |
| CAR-T |
0 |
0.54 |
| Immunotherapy |
0 |
0.37 |
| Leukemia |
0 |
0.37 |
| Acute Lymphoblastic Leukemia |
0 |
0.32 |
| Multiple Myeloma |
0 |
0.32 |
| Hematology |
0 |
0.3 |
| Social Determinants of Health |
0 |
0.29 |
| Stem Cell Research and Therapy |
0 |
0.28 |
| Non-Hodgkin Lymphoma (NHL) |
0 |
0.25 |
| Diversity |
0 |
0.22 |
| T-Lymphocyte |
0 |
0.22 |
| B-Cell Lymphoma |
0 |
0.16 |
| Follicular Lymphoma |
0 |
0.16 |
| Genomic Medicine |
0 |
0.16 |
| Cancer |
0 |
0.15 |
| Lymphoma |
0 |
0.15 |
| Monoclonal Antibody |
0 |
0.15 |
| Refractory |
0 |
0.15 |
| Transfusion |
0 |
0.15 |
| Beta-Thalassemia |
0 |
0.11 |
| Cell Transplantation |
0 |
0.11 |
| Cardiomyopathy |
0 |
0.1 |
| Heart Failure (HF) |
0 |
0.1 |
| Lung Transplantation |
0 |
0.1 |
| Acute Respiratory Distress Syndrome |
0 |
0.07 |
| Adolescent Medicine |
0 |
0.07 |
| Alzheimer Disease |
0 |
0.07 |
| Antigens |
0 |
0.07 |
| Blood |
0 |
0.07 |
| Chemotherapy |
0 |
0.07 |
| Child |
0 |
0.07 |
| Clinical Research |
0 |
0.07 |
| COVID-19 Testing |
0 |
0.07 |
| Cytology |
0 |
0.07 |
| Food and Drug Administration (FDA) |
0 |
0.07 |
| Gene Therapy |
0 |
0.07 |
| Georgia |
0 |
0.07 |
| Heart |
0 |
0.07 |
| Hematologic Malignancies |
0 |
0.07 |
| Hematological Disorders |
0 |
0.07 |
| Hospital |
0 |
0.07 |
| Immunization |
0 |
0.07 |
| Immunomodulator |
0 |
0.07 |
| Lung |
0 |
0.07 |
| Massachusetts |
0 |
0.07 |
| Monoclonal Gammopathy |
0 |
0.07 |
| New York |
0 |
0.07 |
| Pandemic |
0 |
0.07 |
| Prognosis |
0 |
0.07 |
| Proteasome Inhibitor |
0 |
0.07 |
| Receptors |
0 |
0.07 |
| Remission |
0 |
0.07 |
| Severe Acute Respiratory Syndrome |
0 |
0.07 |
| Socioeconomics |
0 |
0.07 |
| Thalassemia |
0 |
0.07 |
| Thromboembolism |
0 |
0.07 |
| Thrombosis |
0 |
0.07 |
| Transplantation |
0 |
0.07 |
| Tumor |
0 |
0.07 |
| Vaccines |
0 |
0.07 |
| Young Adult |
0 |
0.07 |